Quotes 5-day view Delayed London Stock Exchange
02/19/2021
02/22/2021
02/23/2021
02/24/2021
02/25/2021
Date
1215.2(c)
1205.4(c)
1214.8(c)
1213(c)
1216
Last
13 360 499
12 322 245
9 729 702
7 860 276
6 016 905
Volume
-1.92%
-0.81%
+0.78%
-0.15%
+0.25%
Change
Sales 2020
34 076 M
47 819 M
47 819 M
Net income 2020
4 894 M
6 868 M
6 868 M
Net Debt 2020
22 676 M
31 821 M
31 821 M
P/E ratio 2020
12,5x
Yield 2020
6,60%
Sales 2021
34 056 M
47 791 M
47 791 M
Net income 2021
3 474 M
4 874 M
4 874 M
Net Debt 2021
21 652 M
30 385 M
30 385 M
P/E ratio 2021
17,5x
Yield 2021
6,56%
Capitalization
60 694 M
85 740 M
85 173 M
EV / Sales 2020
2,45x
EV / Sales 2021
2,42x
Nbr of Employees
99 437
Free-Float
92,5%
GlaxoSmithkline plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows:
- pharmaceutical products (52%): intended for respiratory diseases (67.5% of net sales), HIV infection (27.7%), immune system disorders (3.5%) ) and cancer (1,3%);
- OTC and parapharmaceutical medicine (26.7%);
- vaccines (21.2%);
- other (0.1%).
Net sales are distributed geographically as...
Notations Surperformance© of GlaxoSmithKline plc
Trading Rating :
Investor Rating :
All news about GLAXOSMITHKLINE PLC
News in other languages on GLAXOSMITHKLINE PLC
Analyst Recommendations on GLAXOSMITHKLINE PLC
GlaxoSmithKline : Sanofi's mRNA COVID-19 vaccine candidate not ready this year, CEO says
Chart GLAXOSMITHKLINE PLC
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends GLAXOSMITHKLINE PLC
Short Term Mid-Term Long Term Trends Bearish Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
26
Average target price
1 567,63 GBX
Last Close Price
1 213,00 GBX
Spread / Highest target
93,7%
Spread / Average Target
29,2%
Spread / Lowest Target
-20,5%
Please enable JavaScript in your browser's settings to use dynamic charts.